Similarly, an adult MS‐LCH patient with the BRAFN486_P490del mutation showed marked improvement in both soft tissue and central nervous system symptoms after receiving targeted MEK inhibitor therapy [34]. The gene discussed is MAP2K7; the disease is myeloid sarcoma.